Table 1.
All of the factors involved in blood malignancies among Iranian population
| STUDY (ET AL) | Year | Type | Gene | population | Results | Prediction |
|---|---|---|---|---|---|---|
| izadifar [27] | 2018 | AML | PVT1 |
134 patients 40 controls |
Over expression in AML-M3 | Diagnosis |
| pashaiefar [28] | 2018 | AML | IRAIN |
64 patients 51 controls |
Under expression. | Poor prognosis |
| ahmadi [29] | 2018 | CLL | MALAT1 |
30 patients 30 controls |
Over expression. | Diagnosis |
| bahari [30] | 2018 | ALL | PAX8-AS1 |
110 patients 120 controls |
Polymorphism was correlated with tumor progression. | Diagnosis |
| hashemi [31] | 2016 | ALL | Lnc-LAMC2 |
110 patients 120 controls |
Polymorphism was correlated with tumor progression. | Diagnosis |
| koolivand [32] | 2018 | AML | miR-155 |
25 patients 25 controls |
Over expression. | Poor prognosis |
| fathullahzadeh [33] | 2016 | CLL | miR-192 |
20 patients 20 controls |
Under expression. | Diagnosis |
| hashemi [34] | 2016 | ALL | miR-34b/c |
110 patients 120 controls |
Polymorphism was correlated with tumor progression. | Diagnosis |
| fallah [35] | 2015 | CML | miR-155, miR-106, miR-16-1, miR-15a, miR-101, and miR-568 | 50 patients | MiR-155 and miR-106 under expressions. MiR-16-1, miR-15a, miR-101, and miR-568 over expressions. | Diagnosis and prognosis |
| seyyedi [36] | 2016 | AML | miR-1, miR-486, and let-7a | 45 patients | Over expressions. | Diagnosis |
| hasani [37] | 2014 | ALL | miR-146a |
75 patients 115 controls |
Polymorphism was correlated with tumor progression. | Diagnosis |
| hashemi [38] | 2017 | ALL | DROSHA |
75 patients 115 controls |
Polymorphism was correlated with tumor progression. | Diagnosis |
| farzaneh [39] | 2016 | CLL and ALL | DICER |
51 patients 29 controls |
Under expression. | Diagnosis |
| rahmani [40] | 2017 | ALL | DNMT1 | 45 patients | Methylation. | Poor prognosis |
| allahbakhshian [41] | 2018 | ALL | IL-6 and IFN-γ |
52 patients 13 controls |
IFN-γ under expression in ALL. IL-6 under expression in T-ALL. | Diagnosis |
| ghavami [42] | 2018 | ALL | IL-27 |
200 patients 210 controls |
Polymorphism was correlated with tumor progression. | Poor prognosis |
| kouzegaran [43] | 2018 | CLL | IL-17A and IL-22 |
78 patients 28 controls |
Over expressions. | Diagnosis |
| sepehrizadeh [44] | 2014 | AML | IL-1β, IL-8, IL-10, and IFN-γ | 46 patients | IL-1β, IL-8, and IL-10 under expressions after chemotherapy. IFN-γ over expression after chemotherapy. | Diagnosis |
| amirzargar [45] | 2005 | CML | TGF-β, IL-4, and IL-10 |
30 patients 40 controls |
TGF-β over expression. IL-4 and IL-10 under expressions. | Diagnosis |
| abdolmaleki [46] | 2018 | AML | PD-1 and CD244 |
30 patients 15 controls |
Over expressions. | Diagnosis |
| taghiloo [47] | 2017 | CLL | GAL-9 and PD-L1 |
25 patients 15 controls |
Over expressions. | Poor prognosis |
| amirghofran [48] | 2001 | AML | CD11b | 70 patients | Correlation with survival. | Diagnosis |
| ramzi [49] | 2018 | AML, ALL, CML | CTLA-4, CD28, and PD-1 |
59 patients 46 controls |
Polymorphisms were correlated with tumor progression. | Diagnosis |
| nasiri [50] | 2013 | ALL, NHL | TNF-α and LT-α |
138 patients 130 controls |
Polymorphisms were correlated with tumor progression. | Diagnosis |
| orouji [51] | 2012 | ALL | HLA-D |
135 patients 150 controls |
Allele frequencies were correlated with tumor progression. | Diagnosis |
| rezvany [52] | 2007 | CLL | HLA-G |
74 patients 12 controls |
Over expression. | Diagnosis |
| amirzargar [53] | 2007 | CML | HLA-D |
50 patients 80 controls |
Allele frequencies were correlated with tumor progression. | Diagnosis |
| khosravi [54] | 2007 | CML | HLA-D |
50 patients 180 controls |
Allele frequencies were correlated with tumor progression. | Diagnosis |
| sarafnejad [55] | 2006 | AML | HLA-D |
60 patients 180 controls |
Allele frequencies were correlated with tumor progression. | Diagnosis |
| moazzeni [56] | 1999 | CLL | HLA-B and HLA-D | 32 patients | Allele frequencies were correlated with tumor progression. | Diagnosis |
| shahsavar [57] | 2010 | AML and ALL | KIR2DS3 |
78 patients 200 controls |
Genotype frequencies were correlated with tumor progression. | Diagnosis |
| noori-daloii [58] | 2013 | GVHD | IL-1α, IL-4Rα, and IL-12 | 91 patients | Polymorphisms were correlated with tumor progression. | Good prognosis |
| kazemi [59] | 2009 | ALL | FCRL1–5 |
73 patients 35 controls |
Under expressions. | Diagnosis |
| pouyanrad [60] | 2019 | ALL | miR-335-5p |
64 patients 30 controls |
Under expression. | Poor prognosis |
| rahgozar [61] | 2014 | ALL | ABCA3, ABCA2, MRD1, and MRP1 |
27 patients 15 controls |
Were correlated with drug resistance. | Poor prognosis |
| mahjoubi [62] | 2008 | AML and ALL | MRP1 |
52 patients 10 controls |
Correlation with poor clinical outcomes. | Poor prognosis |
| mahjoubi [63] | 2012 | ALL | MRP1 |
42 patients 10 controls |
Over expression. | Poor prognosis |
| ghodousi [64] | 2018 | ALL | miR-326 and miR-200c |
46 patients 16 controls |
Under expressions. | Poor prognosis |
| mesrian tanha [65] | 2017 | ALL | ABCC4 | 145 patients | Polymorphism was correlated with tumor progression. | Poor prognosis |
| kazemi [66] | 2018 | Leukemia | HO-1 | 63 patients | Genotype frequencies were correlated with tumor progression. | Good prognosis |
| saadat [67] | 2000 | ALL | GSTM1 |
38 patients 75 controls |
Allele frequencies were correlated with tumor progression. | Diagnosis |
| seghatoleslam [68] | 2014 | ALL | UBE2Q1 |
20 patients 20 controls |
Under expression. | Diagnosis |
| seghatoleslam [69] | 2012 | ALL | UBE2Q2 |
20 patients 20 controls |
Over expression. | Diagnosis |
| zareifar [70] | 2018 | AML | Livin and BIRC5 | 43 patients | Correlation with poor prognosis. | Poor prognosis |
| rostami [71] | 2017 | AML | APAF1 |
101 patients 50 controls |
Methylation. | Diagnosis |
| asgarian-omran [72] | 2010 | CLL | GAL-3 | 85 patients | Under expression. | Poor prognosis |
| daneshbod [73] | 2005 | AML | BCL-2 | 70 patients | Correlation with survival. | Poor prognosis |
| zare-abdollahi [74] | 2016 | AML | BECN1 | 128 patients | Under expression. | Prognosis |
| amirghofran [75] | 2009 | ALL | BCL-2 | 50 patients | Correlation with poor prognosis. | Poor prognosis |
| younesian [76] | 2017 | ALL | RASSF6 | 45 patients | Methylation. | Poor prognosis |
| pashaiefar [77] | 2018 | AML | PARP1 |
65 patients 54 controls |
Over expression. | Poor prognosis |
| pashaiefar [78] | 2018 | AML | PARP1 |
78 patients 19 controls |
Over expression. | Poor prognosis |
| bahari [79] | 2016 | ALL | MTHFR |
100 patients 120 controls |
Polymorphism was correlated with tumor progression. | Diagnosis |
| bahari [80] | 2016 | ALL | SHMT1 |
120 patients 120 controls |
Polymorphism was correlated with tumor progression. | Diagnosis |
| bahari [81] | 2017 | ALL | FHIT |
100 patients 120 controls |
Methylation. | Diagnosis |
| kamali dolatabadi [82] | 2017 | AML | CDKN2B | 59 patients | Methylation. | Diagnosis |
| memarian [83] | 2012 | ALL | WNT-7B, WNT-9A, WNT-16B, WNT-2B, WNT-5A, WNT-7A, WNT-10A |
71 patients 36 controls |
WNT-7B, WNT-9A, and WNT-16B over expressions. WNT-2B, WNT-5A, WNT-7A, and WNT-10A under expressions. | Diagnosis |
| memarian [84] | 2009 | CLL | WNT-3, WNT-4, WNT-5B, WNT-7B, WNT-9A, WNT-10A, WNT-16B, WNT-7A |
62 patients 11 controls |
WNT-3, WNT-4, WNT-5B, WNT-7B, WNT-9A, WNT-10A, and WNT-16B over expressions. WNT-7A under expression. | Diagnosis |
| memarian [85] | 2007 | AML | WNT-3, WNT-7A, Wnt-10A |
16 patients 36 controls |
WNT-3 over expression. WNT-7A and Wnt-10A under expressions. | Diagnosis |
| ghasemi [86] | 2015 | AML | SFRP1, SFRP2 |
43 patients 25 controls |
Methylation. | Diagnosis |
| gholami [87] | 2014 | AML | LATS2 |
32 patients 10 controls |
Over expression. | Poor prognosis |
| rafiee [88] | 2016 | AML | RSK4 |
40 patients 10 controls |
Under expression. | Poor prognosis |
| salarpour [89] | 2017 | AML | CEBPA, RUNX-1 |
96 patients 18 controls |
CEBPA and RUNX-1 over expressions. | Diagnosis |
| ayatollahi [90] | 2017 | AML | WT1 | 126 patients | Over expression. | Diagnosis |
| rezai [91] | 2015 | Leukemia | WT1 |
12 patients 12 controls |
Over expression. | Diagnosis |
| asgarian omran [92] | 2008 | ALL | WT1 |
116 patients 36 controls |
Over expression. | Diagnosis |
| bahari [93] | 2016 | ALL | IKZF1 |
110 patients 120 controls |
Polymorphism was correlated with tumor progression. | Diagnosis |
| rezaei [94] | 2017 | AML | FLT3, NPM1 | 70 patients | Mutation. | Diagnosis |
| nasiri [95] | 2014 | AML | FLT3 | 27 patients | Mutation. | Diagnosis |
| pazhakh [96] | 2011 | AML | NPM1 | 131 patients | Mutation. | Diagnosis |
| zaker [97] | 2010 | AML | FLT3, KIT | 212 patients | Mutation. | Diagnosis |
| jafari ghahfarokhi [98] | 2014 | CLL | ZAP70 | 66 patients | Over expression. | Good prognosis |
| shabani [99] | 2008 | ALL | ROR1, WT1 | 51 patients | Over expressions. | Diagnosis |
| aliparasti [100] | 2013 | AML | VEGF-C |
27 patients 28 controls |
Under expression. | Diagnosis |
| amirpour [101] | 2016 | AML | BAALC |
47 patients 47 controls |
Over expression. | Poor prognosis |
| nadimi [102] | 2016 | ALL, AML | BAALC | 145 patients | Polymorphism was correlated with tumor progression. | Poor prognosis |
| mobasheri [103] | 2006 | ALL | TSGA10 | 52 patients | Expression in ALL cases. | Diagnosis and prognosis |
| hoseinkhani [104] | 2019 | AML | TSGA10, HIF-1α |
30 patients 10 controls |
TSGA10 under expression. HIF-1α over expression. | Diagnosis |